Events & Presentations


Events & Presentations

Upcoming Events
More events are coming soon.
Archived Events
Date Event Details
Jun 20, 2018 9:00 AM EDT
JMP Securities Life Science Conference
New York, NY
Bruce Given, M.D., will present a corporate overview
Jun 15, 2018 2:15 PM EDT
Global Hepatitis Summit 2018
Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver an oral presentation titled, “Interferon-gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC-520 RNAi treatment”
Jun 8, 2018 5:30 PM +08
The Science of HBV Cure 2018
Suntec City, Singapore
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB”
Jun 6, 2018 3:30 PM EDT
Jefferies 2018 Global Healthcare Conference
New York, NY
Chris Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will present a corporate overview
Jun 6, 2018 5:55 PM CEST
41st European Cystic Fibrosis Conference
Belgrade, Serbia
Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled,“Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”
May 21, 2018 9:15 AM PDT
American Thoracic Society (ATS) 2018 International Conference
San Diego
May 10, 2018 4:15 PM PDT
Vascular Discovery: From Genes to Medicine – Scientific Sessions 2018
San Francisco
May 8, 2018 4:30 PM EDT
Arrowhead Fiscal 2018 Second Quarter Results
Apr 25, 2018 4:00 PM EDT
World Orphan Drug Congress USA 2018
Apr 12 - Apr 14, 2018
The EASL International Liver Congress™ 2018

Oral Presentations:

Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection

  • Presentation Reference: PS-030
  • Session: Parallel session: Parallel session: HBV Cure: Pre-clinical studies
  • Date and Time: April 12, 2018 at 5:15 p.m. CET
  • Authors: Christine Wooddell, et al.

ARO-AAT, a subcutaneous RNAi-based therapeutic for alpha-1 antitrypsin-related liver disease, demonstrates liver exposure-response and efficacy in preclinical studies

  • Presentation Reference: PS-147
  • Session: Parallel session: Clinical developments in metabolic and rare disease
  • Date and Time: April 14, 2018 at 9:15 a.m. CET
  • Authors: Christine Wooddell, et al.

Poster Presentation:

RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV

  • Presentation Reference: FRI-362
  • Session: Viral hepatitis B/D: Therapy
  • Session Date and Time: April 13, 2018 from 9 a.m. to 5 p.m. CET
  • Authors: Man-Fung Yuen, et al.